Contrasting Lexicon Pharmaceuticals (NASDAQ:LXRX) & Williston (OTCMKTS:WHCA)

Williston (OTCMKTS:WHCA) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.

Profitability

This table compares Williston and Lexicon Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Williston	N/A	N/A	N/A
Lexicon Pharmaceuticals	-37.46%	-18.64%	-11.79%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Williston and Lexicon Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Williston	0	0	0	0	0.00
Lexicon Pharmaceuticals	1	0	2	0	2.33

Lexicon Pharmaceuticals has a consensus target price of $4.55, indicating a potential upside of 142.02%. Given Lexicon Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe Lexicon Pharmaceuticals is more favorable than Williston.

Earnings and Valuation

This table compares Williston and Lexicon Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Williston	N/A	N/A	N/A	N/A	N/A
Lexicon Pharmaceuticals	$49.80 million	16.77	-$50.34 million	($0.07)	-26.86

Williston has higher earnings, but lower revenue than Lexicon Pharmaceuticals.

Institutional and Insider Ownership

74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. 14.0% of Lexicon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Volatility and Risk

Williston has a beta of 1.58, suggesting that its share price is 58% more volatile than the S&P 500. Comparatively, Lexicon Pharmaceuticals has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500.

Summary

Lexicon Pharmaceuticals beats Williston on 6 of the 10 factors compared between the two stocks.

About Williston

Williston Holding Company, Inc. owns and operates restaurants. The company was incorporated in 2012 and is based in Eden Prairie, Minnesota.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.